# A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

> **NCT04381130** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Everfront Biotech Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** EF-009

## Key facts

- **NCT ID:** NCT04381130
- **Lead sponsor:** Everfront Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381130, "A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04381130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*